Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) Strengthening IP Portfolio Affirm Long Term Prospects

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) impressive start to the year is at risk. The stock has pulled lower from one-year highs in what appears to be a corrective phase. A 20% pullback comes, even on the company strengthening its intellectual patent portfolio.

Cure Price Analysis

The pharmaceutical company is fresh from securing a new patent that details the high loading of the active ingredient in oral thin films. In addition, the company has also secured a patent on oral thin films with Biphasic release of natural ingredients. The announcement of a strategic partnership with Canopy Growth Corp (NYSE:CGC) also went a long way in strengthening the stock’s sentiments in the market prior to the pullback.

The stock’s short-term momentum has turned bearish in recent weeks as short sellers continue to take the fight to the bulls. As the stock continues to trade in a downtrend with a bearish bias, immediate support as part of the correction phase is seen at the $3.20 level.

A sell-off followed by a close below the $3.20 level could give short sellers a reason to continue pushing CURE Pharmaceutical lower. Conversely, the stock stabilizing above the $3.20 level could trigger a bounce-back likely to support further upside action, in continuation of the long-term uptrend.

Strengthening IP Portfolio

Amidst the recent price action activity, CURE Pharmaceutical remains bullish as a long-term play. The strengthening of the patent portfolio should continue to strengthen investors sentiments in the stock.

The new patent on oral thin films with Bi-Phasic release should go along way in expanding the pharmaceutical company’s proprietary drug system CURE film. The patent on high loading of the active ingredient in oral thin films should also enhance the company’s ability to come up with thin edible films that can deliver high doses. The new patents also pave the way for the pharmaceutical company to differentiate its oral thin films for specific drug opportunities such as cannabidiol.

“With an increased consumer demand for natural wellness products, one of our areas of focus is to improve the delivery plant components and extracts in novel ways. With this patent, we continue to build out our capabilities and IP portfolio around Phyto-actives,” explained CEO Rob Davidson.


Cure Pharmaceutical (OTCMKTS:CURR) Continues To Leverage CUREfilm™ To Develop New Drug Delivery Systems

On Wednesday July 24, Cure Pharmaceutical (OTCMKTS:CURR) revealed the acquisition of a patent for a novel drug delivery system. According to the company, the new patent outlines a procedure through which oral film compositions containing over 30% of active ingredient can be enabled.

Cure Pharmaceutical intends to deliver high doses of active ingredients via capsules which are specially made from lipids. The company develops oral thin films (OTF) using CUREfilm™, a proprietary drug delivery system. Particularly, the technology enables the company to load drug active in higher amounts than previously possible.

CURR increases products under CUREfilm™ technology

This patent comes hot on the heels of another one secured in June. In the allowance of patent application, the delivery system enables a bi-phasic release profile. Particularly, the system covers thin films which are edible with natural active ingredients. These ingredients are located in the film matrix as well as the powder coating.

The bi-phasic release profile is used widely in wellness products in the cannabis industry. With the fast growth of the industry, this basically implies that demand for the oral thin films which have a bi-phasic release profile is high. Interestingly, the novel OTF is also built on the proprietary CUREfilm™ technology.

The greatest selling point for the bi-phasic release profile is that drugs are released initially in bursts and then this dissipates into a constant rate of release. As such, users experience the most optimal therapeutic effect the drug.

Building on partnerships and acquisitions

Cure Pharmaceutical’s intentions to mark its territory in the oral thin film sector have been in development for a long time. Particularly, the company opted to enter strategic agreements as well as acquire strategic companies. In June, the company entered a partnership with Canopy Growth to further boost the development of the OTF products.

Commenting on the partnership, Rob Davidson, CEO of CURR, said, “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization. We will leverage our recent patented developments in cannabis-based drug delivery, to formulate an oral thin film product for optimal efficacy and dosing frequency.”

Also, CURR acquired Chemistry Holdings in May in preparation for the venture into the OTF niche. Chemistry Holdings concerns itself with developing drug delivery systems using novel technology.

Pin It on Pinterest